Editas Medicine Announces Pricing of Offering of Common Stock
14 Junho 2023 - 11:06PM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced the pricing of an underwritten
offering of 12,500,000 shares of its common stock at a public
offering price of $10.00 per share, before deducting underwriter
discounts and commissions and estimated offering expenses. Gross
proceeds from the offering are expected to be approximately $125
million. Editas Medicine has granted the underwriters a 30-day
option to purchase up to an additional 1,875,000 shares of common
stock on the same terms and conditions. All of the shares in the
offering are to be sold by Editas Medicine. The offering is
expected to close on or about June 20, 2023, subject to customary
closing conditions.
J.P. Morgan Securities LLC, Cowen and Company, LLC, and Evercore
Group L.L.C. are acting as joint book-running managers for the
offering.
An automatically effective shelf registration statement relating
to the shares of common stock offered in the public offering
described above was filed with the Securities and Exchange
Commission (SEC) on March 1, 2021. The offering is being made only
by means of a prospectus and prospectus supplement that form part
of the registration statement. A preliminary prospectus relating to
and describing the terms of the offering has been filed with the
SEC and is available at www.sec.gov. A final prospectus supplement
relating to the offering will be filed with the SEC. When
available, copies of the final prospectus supplement may be
obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, by telephone at 1-866-803-9204, or by emailing at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by e-mail at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, New York 10055, by telephone at
888-474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Editas MedicineAs a clinical-stage
genome editing company, Editas Medicine is focused on translating
the power and potential of the CRISPR/Cas12a and Cas9 genome
editing systems into a robust pipeline of treatments for people
living with serious diseases around the world. Editas Medicine aims
to discover, develop, manufacture, and commercialize
transformative, durable, precision genomic medicines for a broad
class of diseases. Editas Medicine is the exclusive licensee of
Broad Institute’s Cas12a patent estate and Broad Institute and
Harvard University’s Cas9 patent estates for human medicines.
Forward-Looking StatementsThis press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995
including statements about the anticipated closing of the offering.
The words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors,
including: the satisfaction of customary closing conditions related
to the public offering and the impact of general economic, industry
or political conditions in the United States or internationally;
uncertainties inherent in the initiation of preclinical studies and
clinical trials and clinical development of the Company’s product
candidates; availability and timing of results from preclinical
studies and clinical trials; whether interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products and availability
of funding sufficient for the Company’s foreseeable and
unforeseeable operating expenses and capital expenditure
requirements. These and other risks are described in greater detail
under the captions “Risk Factor Summary” and “Risk Factors”
included in Editas Medicine’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2022 filed with the SEC on February
22, 2023 and in the Company’s subsequent filings with the SEC, the
Company’s preliminary prospectus filed with the SEC on June 14,
2023, and other filings the Company may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and the Company expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media and Investor Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024